

Outline of Consolidated Financial Results for the Year Ended March 31, 2026(IFRS)

May 15, 2026

Name of the listed company: **NIPPON SHINYAKU CO., LTD.**

Code No.: 4516

Representative: Toru Nakai, President and Representative Director

Contact: Kenji Ban, Department Manager and Finance & Accounting Dept.

Scheduled date of annual general meeting of shareholders: June 26, 2026

Scheduled date to commence dividend payments: June 29, 2026

Scheduled date to file annual securities report: June 23, 2026

Preparation of supplementary material on financial results: Yes

Financial result meeting: Yes (for institutional investors, securities analysts and the media)

Listing stock exchange: Tokyo

URL <https://www.nippon-shinyaku.co.jp/>

Tel. +81-75-321-9116

* All amounts are rounded down to the nearest million yen.

1. Consolidated Results for the Year Ended March 31, 2026 (April 1, 2025 to March 31, 2026)

(1) Operating results (¥ million)												
	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Comprehensive income	
		%		%		%		%		%		%
Year ended March 31, 2026	170,771	6.6	35,496	0.1	36,462	0.9	29,728	(8.7)	29,721	(8.7)	52,811	50.5
Year ended March 31, 2025	160,232	8.1	35,450	6.5	36,135	7.5	32,560	25.9	32,558	25.9	35,092	7.6

	Earnings per share (¥)		Return on equity attributable to owners of parent		Profit before tax to total assets		Operating profit to revenue	
	Basic	Diluted						
Year ended March 31, 2026	441.00	441.00		11.0%		11.6%		20.8%
Year ended March 31, 2025	483.40	483.26		13.9%		13.2%		22.1%

Note: Equity-method investments: not applicable

(2) Financial position (¥ million)					
	Total assets	Total equity	Total equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets	Equity attributable to owners of parent per share (¥)
As of March 31, 2026	346,359	291,871	291,551	84.2%	4,325.63
As of March 31, 2025	283,637	247,340	247,028	87.1%	3,666.27

(3) Cash flows (¥ million)				
	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at year-end
Year ended March 31, 2026	27,221	1,982	(9,926)	76,592
Year ended March 31, 2025	36,126	(28,877)	(9,902)	55,241

2. Dividends

	Annual dividends per share (¥)			Total dividends (full term) (¥ million)	Payout ratio (consolidated)	Dividends as a percentage of net assets (consolidated)
	2 nd quarter	Year-end	Annual			
Year ended March 31, 2025	62.00	62.00	124.00	8,354	25.6%	3.6%
Year ended March 31, 2026	62.00	62.00	124.00	8,357	28.1%	3.1%
Year ending March 31, 2027(forecast)	62.00	62.00	124.00		27.6%	

3. Business Forecast for the Year Ending March 31, 2027 (April 1, 2026 to March 31, 2027)

(¥ million)									
	Revenue		Operating profit		Profit before tax		Net income attributable to owners of the parent		Basic earnings per share (¥)
		%		%		%		%	
First-half period	95,000	19.3	17,500	(10.6)	17,800	(11.1)	14,000	(11.2)	207.71
Full term	200,000	17.1	38,000	7.1	38,600	5.9	30,300	1.9	449.55

4. Others

(1) Changes in the scope of consolidation

Inclusion: None

Exclusion: None

Note: Changes in specified subsidiaries involved changes in the scope of consolidation

(2) Changes in accounting policies and accounting estimates, and restatement

1. Changes in accounting policies arising from revision of accounting standards: None

2. Changes in arising from other factors: None

3. Changes in accounting estimates: None

(3) Number of shares outstanding (ordinary shares)

Number of shares outstanding (including treasury stock)

As of March 31, 2026: 70,251,484 shares

As of March 31, 2025: 70,251,484 shares

Number of shares of treasury stock

As of March 31, 2026: 2,850,555 shares

As of March 31, 2025: 2,872,839 shares

Average number of shares outstanding (total for the consolidated period)

As of March 31, 2026: 67,356,171 shares

As of March 31, 2025: 67,352,550 shares

[Reference] Overview of non-consolidated financial results

1.Non-consolidated financial results for the fiscal year ended March 31, 2026 (from April 1, 2025 to March 31, 2026)

(1)Non-consolidated operating results

(¥ million)

	Net sales		Operating profit		Ordinary profit		Profit	
		%		%		%		%
Year ended March 31, 2026	166,149	9.0	34,214	119.2	38,067	126.8	33,015	127.4
Year ended March 31, 2025	152,454	8.6	15,610	(37.8)	16,787	(41.4)	14,515	(35.2)

	Basic earnings per share (¥)	Diluted earnings per share (¥)
Year ended March 31, 2026	489.88	489.88
Year ended March 31, 2025	215.51	215.45

(2)Non-consolidated financial position

(¥ million)

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share (¥)
As of March 31, 2026	303,161	261,280	86.2%	3,876.51
As of March 31, 2025	245,333	216,709	88.3%	3,216.30

Reference: Equity

As of March 31, 2026: ¥261,280million

As of March 31, 2025: ¥216,709 million

Note:

This summary of financial results is exempt from the audit procedures under the Financial Instruments and Exchange Act. At the time of disclosure, published figures in this financial release have not been completed to a review of financial statements based on the Financial Instruments and Exchange Law.

The above forecasts are based on data available as of the date of release of this document as well as assumptions based on uncertain factors, which might have a material effect on the Company's performance in the future. Readers are advised that actual results may differ substantially from the above forecasts due to various unforeseeable factors.

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Brand name	Indications	April to September		Annual			
		FY2025	FY2026 (Estimated)	FY2024	Percentage change	FY2025	FY2026 (Estimated)
Viltepso (Japan) (U.S.)	Duchenne muscular dystrophy	10,349 (2,386) (7,963)	11,100 (2,400) (8,700)	21,782 (4,664) (17,117)	△ 2.7% 2.4% △ 4.1%	21,188 (4,775) (16,413)	22,300 (4,800) (17,500)
Uptravi	Pulmonary arterial hypertension/ Chronic thromboembolic pulmonary hypertension	8,448	9,200	14,971	17.5%	17,593	19,200
Erleada	Prostate cancer	-	7,200	-	-	5,961	14,400
Vyxeos	High-risk acute myeloid leukemia	2,941	3,100	5,139	11.7%	5,742	6,500
Gazyva	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	2,451	2,500	4,821	5.3%	5,076	5,100
Fintepla	Seizures associated with Dravet syndrome/ Seizures associated with Lennox-Gastaut syndrome	1,765	3,000	2,067	92.5%	3,980	6,100
Defitelio	Sinusoidal obstruction syndrome	1,252	1,300	2,364	6.3%	2,514	2,600
Cialis	Erectile dysfunction	1,119	1,000	2,425	△ 8.4%	2,221	2,000
Deramiceol (U.S.)	Duchenne muscular dystrophy cardiomyopathy	-	-	-	-	-	11,400
Profit in co-promotion		4,792	4,500	9,170	△ 2.2%	8,964	8,600
Revenues from the licensing of industrial property rights		24,181	27,300	45,585	8.5%	49,457	53,000
Pharmaceuticals		68,561	83,500	138,654	7.1%	148,484	176,500
Functional Food		11,086	11,500	21,577	3.3%	22,287	23,500
Revenue		79,647	95,000	160,232	6.6%	170,771	200,000

(Revenue based on the NHI drug price)

Jaypirca※	Mantle cell lymphoma Chronic lymphocytic leukemia	1,086	-	780	236.5%	2,626	-
-----------	--	-------	---	-----	--------	-------	---

※Sales forecasts for Jaypirca are not disclosed.

Nippon Shinyaku: R&D Pipeline List

May 15, 2026

Stage	Code No. (Generic name)	Therapeutic field	Indications	Origin	Development	Target area for application
Launch Phase III	NS-065/NCNP-01 (viltolarsen)	intractable and rare diseases	Duchenne muscular dystrophy	Co-development with National Center of Neurology and Psychiatry	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Filed	CAP-1002 (deramiocel)	intractable and rare diseases	Duchenne muscular dystrophy cardiomyopathy	Partnered with Capricor Therapeutics, Inc.	Capricor Therapeutics, Inc.	U.S.
Filed	RGX-121 (clemidrogene lanaparvovect)	intractable and rare diseases	Mucopolysaccharidosis Type II	Partnered with REGENXBIO Inc.	REGENXBIO Inc.	U.S.
Filed	GA101 (obinutuzumab)	intractable and rare diseases	Idiopathic nephrotic syndrome	In-licensed from Chugai Pharmaceutical Co., Ltd.	Co-development with Chugai Pharmaceutical Co., Ltd.	Japan
Phase III	ZX008 (fenfluramine hydrochloride)	intractable and rare diseases	CDKL5 deficiency disorder	Distribution partnership with UCB S.A. (formerly known as Zogenix, Inc.)	UCB S.A. (formerly known as Zogenix, Inc.)	Japan
Phase III	GA101 (obinutuzumab)	intractable and rare diseases	Lupus nephritis	In-licensed from Chugai Pharmaceutical Co., Ltd.	Co-development with Chugai Pharmaceutical Co., Ltd.	Japan
			Extra renal lupus			
Phase III	CAP-1002 (deramiocel)	intractable and rare diseases	Duchenne muscular dystrophy	Partnered with Capricor Therapeutics, Inc.	Capricor Therapeutics, Inc.	U.S.
Phase III	LY3527727 (pirtobrutinib)	hematologic malignancies	Mantle cell lymphoma	Alliance agreement in Japan with Eli Lilly Japan K.K.	Eli Lilly Japan K.K.	Japan
			Chronic lymphocytic leukemia			
Phase III	NS-304 (selexipag)	cardiovascular	Arteriosclerosis obliterans	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan
Phase II	NS-580	gynecology	Endometriosis	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan
		urological diseases	Chronic prostatitis / Chronic pelvic pain syndrome			
Phase II	NS-089/NCNP-02 (brogidirsen)	intractable and rare diseases	Duchenne muscular dystrophy	Co-development with National Center of Neurology and Psychiatry	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Phase II	NS-229	intractable and rare diseases	Eosinophilic granulomatosis with polyangiitis	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Preparation for Phase II	NS-035	intractable and rare diseases	Fukuyama congenital muscular dystrophy	Co-development with Kobe University	Nippon Shinyaku Co., Ltd.	Japan
Preparation for Phase II	NS-863	cardiovascular	Pulmonary arterial hypertension	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan/U.S.
			Pulmonary hypertension associated with interstitial lung disease			
Phase I/II	NS-050/NCNP-03	intractable and rare diseases	Duchenne muscular dystrophy	Co-development with National Center of Neurology and Psychiatry	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Phase I/II	ATSN-101	intractable and rare diseases	GUCY2D-associated Leber congenital amaurosis	In-licensed from Atsena Therapeutics, Inc.	Atsena Therapeutics, Inc.	U.S.
Phase I/II	RGX-111	intractable and rare diseases	Mucopolysaccharidosis Type I	Partnered with REGENXBIO Inc.	REGENXBIO Inc.	U.S.
Phase I	NS-917 (radgocitabine)	hematologic malignancies	Relapsed/refractory acute myeloid leukemia	In-licensed from Delta-Fly Pharma, Inc.	Nippon Shinyaku Co., Ltd.	Japan
Phase I	NS-025	urological diseases	Urological diseases	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan
Phase I	NS-245	inflammatory diseases	Inflammatory diseases	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan